Larvol Delta - Clinical-Study-of-VG161-Combined-With-Camrelizumab-in-Patients-With-Advanced-Primary-Hepatocellular-Carcinoma

VG161 - ViroGin Biotech

AiRuiKa (camrelizumab) - HLB Bio Group

http://clinicaltrials.gov/ct2/show/NCT06124001

Nov 9, 2023

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next